A rare case of malignant syphilis after adalimumab therapy due to Crohn's disease associated with bariatric surgery

Diagn Microbiol Infect Dis. 2019 Sep;95(1):89-92. doi: 10.1016/j.diagmicrobio.2019.04.009. Epub 2019 Jun 21.

Abstract

Malignant syphilis (also known lues maligna) is a rare and severe variant of secondary syphilis. It is most commonly seen in patients who are infected with human immunodeficiency virus (HIV), and rarely, it can occur in immunocompetent individuals. The exact mechanism of the development of malignant syphilis is not clear. It could probably be associated with immunosuppression, inappropriate immune response of the host, or virulent strain of Treponema pallidum. Coexistence of immunosuppression and inappropriate immune response may predispose to develop malignant syphilis in HIV-infected patients with immune reconstitution inflammatory syndrome. Herein, we report the first case of malignant syphilis after adalimumab therapy for Crohn's disease due to bariatric surgery and discuss the underlying possible pathogenic mechanisms.

Keywords: Adalimumab; Bariatric surgery; Crohn's disease; Malignant syphilis.

Publication types

  • Case Reports

MeSH terms

  • Adalimumab / adverse effects*
  • Adalimumab / therapeutic use
  • Adult
  • Anti-Bacterial Agents / therapeutic use
  • Anti-Inflammatory Agents / adverse effects*
  • Anti-Inflammatory Agents / therapeutic use
  • Bariatric Surgery / adverse effects*
  • Crohn Disease / drug therapy
  • Crohn Disease / etiology*
  • Female
  • Humans
  • Penicillin G Benzathine / therapeutic use
  • Syphilis / diagnosis*
  • Syphilis / drug therapy
  • Syphilis / etiology
  • Syphilis / pathology
  • Treatment Outcome
  • Treponema pallidum / drug effects
  • Treponema pallidum / isolation & purification*

Substances

  • Anti-Bacterial Agents
  • Anti-Inflammatory Agents
  • Adalimumab
  • Penicillin G Benzathine

Supplementary concepts

  • Syphilis, secondary